License to AstraZeneca Sample Clauses

License to AstraZeneca. Subject to the terms and conditions of this Agreement, FibroGen China hereby grants AstraZeneca a co-exclusive (with FibroGen Cayman, who retains a licensable right to develop, use, sell, offer for sale, import and Commercialize Products in the Field in the Territory), royalty-bearing, sublicensable (solely as permitted in accordance with Section 7.3) license under the FibroGen China Technology and the Marks to Develop (solely in accordance with the applicable Development Plan), use, sell, offer for sale, import and Commercialize, but not Manufacture, Products in the Field in the Territory. With respect to any Product hereunder, notwithstanding the foregoing, AstraZeneca shall (a) not exercise any of the co-exclusive rights to Develop granted hereunder until FibroGen WFOE has sole ownership of and is the sole named party for the regulatory licenses in the Territory, which shall include without limitation the (i) New Drug License, (ii) Product Approval Code, (iii) Manufacturing License, and (iv) GMP License, and for such licenses any other necessary, related or successor licenses, and (b) take all actions and execute all documents reasonably necessary to ensure that FibroGen WFOE shall solely hold such licenses. FibroGen shall promptly notify AstraZeneca upon the issuance of such licenses.

License to AstraZeneca. (a) Subject to the terms and conditions of this Agreement, BIND hereby grants to AstraZeneca and its Affiliates an exclusive (including with regard to BIND and its Affiliates) worldwide, royalty-bearing license in the Field under the Exclusive Licensed Technology to research, develop (including to conduct Clinical Development), Manufacture, Commercialize, import, use, sell, offer for sale and otherwise exploit a Product Candidate alone and in the Product. (b) BIND and its Affiliates hereby grants to AstraZeneca a non-exclusive worldwide, royalty-bearing license in the Field under the Non-Exclusive Licensed Technology to research, develop (including to conduct Clinical Development), Manufacture, Commercialize, import, use, sell, offer for sale and otherwise exploit a Product Candidate alone and in the Product in the Field. (c) Notwithstanding the foregoing licenses in Sections 7.1(a) and (b), any license granted under Patents and Know-How Controlled by BIND necessary or useful for the manufacturing process for the Product Candidate alone and in the Product shall be limited to the Manufacture by AstraZeneca in its own manufacturing facility or in the facility of a Third Party manufacturer solely for manufacturing and supply to AstraZeneca, and is further subject to those conditions and obligations in this Agreement.

License to AstraZeneca. Subject to the terms and conditions of this Agreement, Ironwood hereby grants to AstraZeneca, a perpetual (except as otherwise provided in Section 10), exclusive, nontransferable (except as set forth in Section 12.9 or Section 12.10) license, with the right to grant sublicenses as described in Section 2.6, and subject only to the rights reserved to Ironwood to the extent necessary to perform its obligations or exercise its rights hereunder, under the Ironwood Technology and Ironwood’s interest in the Joint Technology and Development Data (a) to (A) Develop the Licensed Compound and Products in the Field anywhere in the world for Commercialization in the Field in the Territory and (B) Commercialize the Licensed Compound and Products in the Field in the Territory, and (b) to Manufacture, make or have made the Licensed Compound or Products anywhere in the world for (x) Development of the Licensed Compound and Products in the Field anywhere in the world for Commercialization in the Field in the Territory or (y) Commercialization of the Licensed Compound and Products in the Field in the Territory; provided that, for clarity, the foregoing license grant with respect to Switzerland shall be limited to the Permitted Purpose. Notwithstanding the foregoing, Ironwood reserves the right under the Ironwood Technology and Ironwood’s interest in the Joint Technology and the Development Data to (i) subject to Section 5.2.5(c), develop and manufacture the Licensed Compound and Products inside or outside of the Territory in support of development or commercialization of the Licensed Compound and Products outside of the Territory, (ii) develop and commercialize the Licensed Compound and Products in the Territory outside of the Field, and (iii) commercialize the Licensed Compound and Products outside of the Territory, in each case ((i) through (iii)) in accordance with any applicable terms of this Agreement. Subject to Section 7.3, [**].

License to AstraZeneca. The Institution and the Principal Investigator agree that, if either publishes the results of the Multi-Center Study or the Study, AstraZeneca is hereby granted an irrevocable, royalty-free license to make and distribute copies of such publication under any copyright privileges that the Institution and the Principal Investigator may have. AstraZeneca also shall have the right to publish independently the results of the Multi-Center Study and the Study. The Institution and the Principal Investigator shall, in any agreement with a journal or other publisher to publish the results of the Multi-Center Study or the Study, use reasonable efforts to reserve expressly all copyright rights necessary to grant AstraZeneca the license and rights contained herein.

License to AstraZeneca